“Being the largest generic drug manufacturer in the world, and supplier of more than 50% of global demand for various vaccines, India had all the resources and know-how to fulfil the need of the masses of various geographies. As an allied industry, our Fine and Specialty Chemicals segment served as a perfect foil to the Indian Pharma industry during the COVID pandemic by supplying all the Raw materials and excipients that are needed to manufacture the vital life-saving drugs and vaccines in adequate quantities and on time”. Thus opines Dr. Rashmi Ranjan Mohanty, Co-founder and CTO of Advent Chembio Pvt. Ltd., a leading Fine and Specialty manufacturer in India.
Dr. Mohanty is responsible for quality, research & development as well as innovation at Advent. He is also accountable for the implementation of the company’s quality policies and systems based on cGMP guidelines. A holder of M.Phil. and Ph.D. degrees in Chemistry from Utkal University, Odisha, he has a working experience of nearly 3 decades in research, academics and industry (including his last stint at RFCL Limited as Head of R&D, QA & QC & Custom Synthesis division).
Additionally, he carried out his post-doctoral research in the field of Chiral Amines under the guidance of Prof. Thomas Nugent at Jacobs University Bremen, Germany and has research publications in international journals of repute like “Organic Letters”, “Advanced Synthesis & Catalysis”, “European Journal of Organic Chemistry” etc. and a European Patent to his credit.
The Microbioz India team had a conversation with Dr. Mohanty to understand the history and operations of Advent, one of the companies behind this growth story in the Fine and Specialty Chemicals Segment. Take a look at the chat.
